Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.67 |
| ▸ | GPR3 | P46089 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.49 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.46 |
| ▸ | KDM4A | O75164 | 1/20 | 0.42 |
| ▸ | KDM4B | O94953 | 1/20 | 0.42 |
| ▸ | KDM5C | P41229 | 1/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.42 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.42 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31135312 | 1.00 | KDM4E (0.67) | KDM4EGPR3HTTALDH1A1NCOA1 | |
| SCHEMBL8067522 | 0.85 | KDM4E (0.63) | KDM4EGPR3HTTALDH1A1NCOA1 | |
| SCHEMBL2413552 | 0.84 | KDM4E (0.67) | KDM4EGPR3HTTALDH1A1NCOA1 | |
| SCHEMBL29802283 | 0.84 | KDM4E (0.67) | KDM4EGPR3HTTALDH1A1NCOA1 | |
| SCHEMBL2407978 | 0.84 | KDM4E (0.67) | KDM4EGPR3HTTALDH1A1NCOA1 | |
| Phenanthridine SCHEMBL28242096 | 0.82 | KDM4E (0.69) | KDM4EGPR3HTTALDH1A1NCOA1 | |
| Phenanthridine SCHEMBL9106884 | 0.81 | GPR3 (1.00) | KDM4EGPR3ALDH1A1CYP3A4LMNA | |
| Phenanthridine SCHEMBL30823553 | 0.81 | GPR3 (1.00) | KDM4EGPR3ALDH1A1CYP3A4LMNA | |
| Phenanthridine SCHEMBL8666 | 0.81 | GPR3 (1.00) | KDM4EGPR3ALDH1A1CYP3A4LMNA | |
| Phenanthridine SCHEMBL30914262 | 0.81 | GPR3 (1.00) | KDM4EGPR3ALDH1A1CYP3A4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357188-A1 | PHENANTHRENE ORGANIC COMPOUND AND USE THEREOF | WUHAN TIANMA MICROELECTRONICS CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230151020-A1 | HETEROCYCLIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE | WUHAN TIANMA MICROELECTRONICS CO., LTD. (CN) | 2023-05-18 | — | — | US | disclosed |
| US-20230151020-A1 | HETEROCYCLIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE | WUHAN TIANMA MICROELECTRONICS CO., LTD. (CN) | 2023-05-18 | — | — | US | disclosed |
| US-11066351-B2 | Organic compound, three-dimensional organic framework formed by using organic compound, separation sieve and optical layer, which comprise organic framework, and optical device comprising optical layer as optical amplification layer | IUCF-HYU (INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY) (KR) | 2021-07-20 | — | — | US | disclosed |
| US-10472380-B2 | Platinum compounds having a heterocycle ligand, nanoparticles, and uses thereof | PLACON THERAPEUTICS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-20190031586-A1 | ORGANIC COMPOUND, THREE-DIMENSIONAL ORGANIC FRAMEWORK FORMED BY USING ORGANIC COMPOUND, SEPARATION SIEVE AND OPTICAL LAYER, WHICH COMPRISE ORGANIC FRAMEWORK, AND OPTICAL DEVICE COMPRISING OPTICAL LAYER AS OPTICAL AMPLIFICATION LAYER | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY (KR) | 2019-01-31 | — | — | US | disclosed |
| US-9947877-B2 | Organic light emitting display device | LG DISPLAY CO., LTD. (KR) | 2018-04-17 | — | — | US | disclosed |
| US-20170349615-A1 | PLATINUM COMPOUNDS HAVING A HETEROCYCLE LIGAND, NANOPARTICLES, AND USES THEREOF | XLINK THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| US-9780310-B2 | Heterocyclic compound for organic electroluminescent device and its application | TOSOH CORPORATION (JP) | 2017-10-03 | — | — | US | disclosed |
| US-9780310-B2 | Heterocyclic compound for organic electroluminescent device and its application | TOSOH CORPORATION (JP) | 2017-10-03 | — | — | US | disclosed |
| US-9771387-B2 | Platinum compounds having a heterocycle ligand, nanoparticles, and uses thereof | PLACON THERAPEUTICS (US) | 2017-09-26 | — | — | US | disclosed |
| US-20160285010-A1 | ORGANIC LIGHT EMITTING DISPLAY DEVICE | LG DISPLAY CO., LTD. (KR) | 2016-09-29 | — | — | US | disclosed |
| US-20160152646-A1 | PLATINUM COMPOUNDS HAVING A HETEROCYCLE LIGAND, NANOPARTICLES, AND USES THEREOF | XLINK THERAPEUTICS, INC. | 2016-06-02 | — | — | US | disclosed |
| US-20160056388-A1 | HETEROCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENT DEVICE AND ITS APPLICATION | TOSOH CORPORATION (JP) | 2016-02-25 | — | — | US | disclosed |
| US-20160056388-A1 | HETEROCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENT DEVICE AND ITS APPLICATION | TOSOH CORPORATION (JP) | 2016-02-25 | — | — | US | disclosed |
| WO-2015009841-A2 | PLATINUM COMPOUNDS HAVING A HETEROCYCLE LIGAND, NANOPARTICLES, AND USES THEREOF | BLEND THERAPEUTICS (US) | 2015-01-22 | — | — | WO | disclosed |
| US-20140088066-A1 | PLATINUM COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | BLEND THERAPEUTICS (US) | 2014-03-27 | — | — | US | disclosed |
| WO-2014043243-A2 | PLATINUM COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | BLEND THERAPEUTICS (US) | 2014-03-20 | — | — | WO | disclosed |
| WO-2011105700-A1 | NOVEL ORGANIC ELECTROLUMINESCENT COMPOUNDS AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME | ROHM AND HAAS ELECTRONIC MATERIALS KOREA LTD. (KR) | 2011-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349615-A1 | PLATINUM COMPOUNDS HAVING A HETEROCYCLE LIGAND, NANOPARTICLES, AND USES THEREOF | TP53, PDCD1LG2, IDH1 | KDM4E 4074/4885GPR3 2899/4885HTT 353/4885 |
| US-20160152646-A1 | PLATINUM COMPOUNDS HAVING A HETEROCYCLE LIGAND, NANOPARTICLES, AND USES THEREOF | TP53, PDCD1LG2, IDH1 | KDM4E 4074/4885GPR3 2899/4885HTT 353/4885 |
| US-20140088066-A1 | PLATINUM COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | APEX1, DPYD, VHL | KDM4E 2370/4885GPR3 3910/4885HTT 189/4885 |
| US-20160056388-A1 | HETEROCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENT DEVICE AND ITS APPLICATION | AOC2, AZI2, KCNH2 | KDM4E 995/4885GPR3 3295/4885HTT 1809/4885 |
| US-20230357188-A1 | PHENANTHRENE ORGANIC COMPOUND AND USE THEREOF | AHR, ORAI3, WNT3 | KDM4E 3942/4885GPR3 8/4885HTT 613/4885 |
| US-11066351-B2 | Organic compound, three-dimensional organic framework formed by using organic compound, separation sieve and optical layer, which comprise organic framework, and optical device comprising optical layer as optical amplification layer | OR10J3, POF1B, ORC3 | KDM4E 2692/4885GPR3 1337/4885HTT 4000/4885 |
| US-20190031586-A1 | ORGANIC COMPOUND, THREE-DIMENSIONAL ORGANIC FRAMEWORK FORMED BY USING ORGANIC COMPOUND, SEPARATION SIEVE AND OPTICAL LAYER, WHICH COMPRISE ORGANIC FRAMEWORK, AND OPTICAL DEVICE COMPRISING OPTICAL LAYER AS OPTICAL AMPLIFICATION LAYER | OR10J3, POF1B, ORC3 | KDM4E 2692/4885GPR3 1337/4885HTT 4000/4885 |
| US-20230151020-A1 | HETEROCYCLIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE | OCIAD1, OCIAD2, EHD1 | KDM4E 2555/4885GPR3 4426/4885HTT 26/4885 |
| US-10472380-B2 | Platinum compounds having a heterocycle ligand, nanoparticles, and uses thereof | TP53, PDCD1LG2, IDH1 | KDM4E 4074/4885GPR3 2899/4885HTT 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.